- Home
- AACB vs XOMA Comparison
AACB vs XOMA Comparison
Compare AACB & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AACB | XOMA |
|---|---|---|
| Founded | 2024 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.6M | 308.6M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AACB | XOMA |
|---|---|---|
| Price | $10.34 | $25.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $63.25 |
| AVG Volume (30 Days) | 32.8K | ★ 690.1K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $47,106,000.00 |
| Revenue This Year | N/A | $77.29 |
| Revenue Next Year | N/A | $29.30 |
| P/E Ratio | ★ N/A | $30.26 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $9.85 | $18.35 |
| 52 Week High | $10.39 | $39.92 |
Technical Indicators
Market Signals| Indicator | AACB | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 45.71 |
| Support Level | $10.29 | $24.70 |
| Resistance Level | $10.32 | $27.87 |
| Average True Range (ATR) | 0.00 | 1.51 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 40.00 | 35.87 |
Price Performance
Historical ComparisonAbout AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.